We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
FirstEnergy
FE
$28.4B
| $51.6M | 0.08% |
1,151,931
+95,161
| +9% | +$4.37M |
|
202
Tetra Tech
TTEK
$8.77B
| $50.3M | 0.08% |
1,499,337
-4,970
| -0.3% | -$168K |
|
203
Warner Bros
WBD
$64.3B
| $50.2M | 0.08% |
1,742,937
-39,094
| -2% | -$914K |
|
204
Apollo Global Management
APO
$69B
| $50.1M | 0.08% |
346,424
-5,205
| -1% | -$691K |
|
205
CenterPoint Energy
CNP
$28.3B
| $50.1M | 0.08% |
1,307,625
-127,080
| -9% | -$4.95M |
|
206
Corning
GLW
$107B
| $49.7M | 0.08% |
568,048
-5,622
| -1% | -$484K |
|
207
Electronic Arts
EA
$52.4B
| $49.6M | 0.08% |
242,560
-6,833
| -3% | -$1.38M |
|
208
Fidelity National Information Services
FIS
$24.2B
| $49.3M | 0.08% |
741,805
+76,697
| +12% | +$5.06M |
|
209
Seagate
STX
$173B
| $49.2M | 0.08% |
178,818
+117
| +0.1% | +$30.4K |
|
210
Hartford Financial Services
HIG
$39.9B
| $49.1M | 0.08% |
356,502
+81,303
| +30% | +$10.7M |
|
211
L3Harris
LHX
$55.4B
| $48.8M | 0.08% |
166,245
-10,671
| -6% | -$3.08M |
|
212
Kaspi.kz JSC
KSPI
$16.6B
| $48.5M | 0.08% |
621,339
-158,307
| -20% | -$12M |
|
213
United Parcel Service
UPS
$88.9B
| $48.5M | 0.08% |
488,635
+18,601
| +4% | +$1.74M |
|
214
Essex Property Trust
ESS
$19.1B
| $48.5M | 0.08% |
185,175
+755
| +0.4% | +$195K |
|
215
Sarepta Therapeutics
SRPT
$1.64B
| $48.5M | 0.08% |
2,251,593
+268,829
| +14% | +$5.67M |
|
216
Cardinal Health
CAH
$53.7B
| $48.3M | 0.07% |
235,069
+2,335
| +1% | +$439K |
|
217
Cintas
CTAS
$86.6B
| $47.8M | 0.07% |
254,160
-18,769
| -7% | -$3.54M |
|
218
Arthur J. Gallagher & Co
AJG
$69.1B
| $47.7M | 0.07% |
184,399
-2,026
| -1% | -$536K |
|
219
Royal Caribbean
RCL
$86.8B
| $47.7M | 0.07% |
171,048
-12,420
| -7% | -$3.51M |
|
220
Hewlett Packard
HPE
$58.8B
| $47.5M | 0.07% |
1,979,595
+41,593
| +2% | +$980K |
|
221
Carrier Global
CARR
$49.8B
| $47.4M | 0.07% |
896,190
-9,299
| -1% | -$517K |
|
|
222
Ascendis Pharma A/S
ASND
$16.5B
| $47.3M | 0.07% |
221,677
+172,251
| +349% | +$35.6M |
|
223
Ametek
AME
$53.9B
| $47.2M | 0.07% |
230,004
-1,549
| -0.7% | -$301K |
|
224
Western Digital
WDC
$159B
| $46.9M | 0.07% |
272,487
+28,227
| +12% | +$4.28M |
|
225
Ferguson
FERG
$43.9B
| $46.4M | 0.07% |
208,439
+4,832
| +2% | +$1.15M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.